A discrete choice experiment on oral and injection treatment preferences among moderate‐to‐severe psoriasis patients in Japan

Abstract

is a chronic inflammatory skin disease in which approximately 90% of patients are characterized by well-demarcated and erythematous plaques covered with silvery scales. 1 The prevalence of PsO ranges from 0.09% to 11.4% worldwide, with an estimated 100 million people affected. 2,3 A claims database study using data from 2010 to 2011 reported that more than 400 000 people are living with PsO in Japan, with a prevalence estimated to be 0.34%. 4 The physical, economic, and psychological burdens of PsO are substantial. 5 This disease negatively affects social functioning, including decreased work efficiency and distress at work due to skin symptoms such itching or redness. 6 Occupational impairment leads to lower wages or barriers to promotion, further exacerbating the psychosocial burden of PsO. 7 Additionally, a large proportion of patients experience

Treatment patterns of systemic drug use in Japanese patients with plaque psoriasis: A retrospective chart review

“…In this study, oral drugs tended to have shorter persistence than biologics such as IL‐17 and IL‐23 inhibitors, although PDE4 inhibitors showed relatively longer persistence in oral drugs. Japanese patients with PsO prefer oral to injectable drugs as systemic treatment, 29 and clinical challenges remain for long‐term treatment with oral drugs. The drug persistence of biologics and oral drugs was comparable with that reported in our previous 1‐year retrospective study 20 .…”

Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A (LY3509754): A Phase I Randomized Placebo‐Controlled Study

“…However, despite these advantages, some patients may dislike injectables due to fear of needles, concerns about syringe preparation and disposal, and challenges in receiving treatment while traveling. 11,12 Treatment with mAbs can also be less practical for psoriatic diseases because they are typically life-long conditions and require long-term management. For example, treatment regimens might be impacted by supply chain complexity and longer-term administration can elicit anti-drug antibodies, which may diminish treatment responses.…”

“…13,14 Small molecules targeting IL-17A signaling may represent another therapeutic option and an alternative to mAbs for some patients. 11,12 Small molecules can be designed for oral delivery, which may be more desirable than an injectable, and their shorter half-lives vs. the mAbs may benefit patients requiring a break from medication. Indeed, oral therapies including the PDE4 inhibitor apremilast and Tyk2 inhibitors are effective options for patients with psoriasis.…”

“…The mAb inhibition of the IL‐17 pathway has proven to be highly efficacious, safe, and durable, 7 with the added advantages common to all mAbs that they are target‐specific and have relatively long half‐lives, which allow extended dosing intervals. However, despite these advantages, some patients may dislike injectables due to fear of needles, concerns about syringe preparation and disposal, and challenges in receiving treatment while traveling 11,12 . Treatment with mAbs can also be less practical for psoriatic diseases because they are typically life‐long conditions and require long‐term management.…”